Drugs / Plasmin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00347646 | Sep 2006 → May 2007 | vitreoretinal degeneration | Bausch & Lomb Incorporated | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01222117 | Dec 2010 → Dec 2015 | peripheral arterial occlusive disease 1 | Grifols Therapeutics LLC | Completed | No outcome recorded |
| Phase 2 | NCT00348439 | Apr 2006 → Aug 2007 | vitreoretinal degeneration | Bausch & Lomb Incorporated | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasmin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00347646 ↗ |
| Known as | Plasmin (Human) | “Plasmin (Human)” NCT01222117 ↗ |
| Modality | Protein / enzyme biologic | “Human-derived plasmin reconstituted with sterile sodium chloride for intravitreal injection.” NCT00347646 ↗ |
| Route | Intravitreal | “single intravitreal injection” NCT00347646 ↗ |